A US Senate Finance Committee hearing on drug pricing focused on addressing the role of pharmacy benefit managers (PBMs) in determining cost to patients. NCODA notes that the Executives from these companies dodged key questions around their policies’ impact on cancer patients. We will continue to support state legislation that increases transparency with the PBMs and passes savings to patients. read more